Biogen Inc. (BIT:1BIIB)
Italy · Delayed Price · Currency is EUR | Market Cap | 32.13B +68.6% |
| Revenue (ttm) | 9.07B +2.3% |
| Net Income | 306.01M -78.4% |
| EPS | 2.10 -78.7% |
| Shares Out | n/a |
| PE Ratio | 93.85 |
| Forward PE | 16.43 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2 |
| Open | 198.78 |
| Previous Close | 201.05 |
| Day's Range | 198.78 - 198.78 |
| 52-Week Range | 121.50 - 201.80 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar refe... [Read more]
Financial Performance
In 2025, Biogen's revenue was $9.89 billion, an increase of 2.22% compared to the previous year's $9.68 billion. Earnings were $1.29 billion, a decrease of -20.79%.
Financial numbers in USD Financial StatementsNews
Biogen Provides Update on Private Payer Coverage for ZURZUVAE™ (zuranolone)
TORONTO--(BUSINESS WIRE)--Biogen Canada Inc. today announced that many group benefit health plans now reimburse ZURZUVAE™ (zuranolone), for the treatment of moderate or severe postpartum depression (P...
Biogen price target raised to $300 from $280 at Guggenheim
Guggenheim raised the firm’s price target on Biogen (BIIB) to $300 from $280 and keeps a Buy rating on the shares.
Biogen price target raised to $270 from $251 at H.C. Wainwright
H.C. Wainwright analyst Ananda Ghosh raised the firm’s price target on Biogen (BIIB) to $270 from $251 and keeps a Buy rating on the shares. The firm cites the company’s…
Biogen price target raised to $275 from $255 at Freedom Broker
Freedom Broker analyst Ilya Zubkov raised the firm’s price target on Biogen (BIIB) to $275 from $255 and keeps a Buy rating on the shares following the Q3 report. Biogen’s…
Biogen price target raised to $272 from $256 at RBC Capital
RBC Capital raised the firm’s price target on Biogen (BIIB) to $272 from $256 and keeps an Outperform rating on the shares after its Q3 earnings beat. Investor focus remains…
Biogen price target raised to $260 from $250 at TD Cowen
TD Cowen raised the firm’s price target on Biogen (BIIB) to $260 from $250 and keeps a Buy rating on the shares. The firm updated its model following solid Q3…
Biogen price target raised to $225 from $212 at Wedbush
Wedbush raised the firm’s price target on Biogen (BIIB) to $225 from $212 and keeps a Neutral rating on the shares. The firm notes the company reported a roughly $168M…
Biogen price target raised to $300 from $270 at UBS
UBS raised the firm’s price target on Biogen (BIIB) to $300 from $270 and keeps a Buy rating on the shares. The firm sees a “positive” setup into the Phase…
Biogen upgraded to Buy from Hold at Argus
Argus upgraded Biogen (BIIB) to Buy from Hold with a $280 price target The company has benefited in recent quarters from strength in its Rare Diseases portfolio, which more than…
Biogen price target raised to $238 from $231 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Biogen (BIIB) to $238 from $231 and keeps an Equal Weight rating on the shares.
Biogen price target raised to $272 from $248 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Biogen (BIIB) to $272 from $248 and keeps a Buy rating on the shares. The firm updated its model following…
Biogen price target raised to $290 from $256 at Needham
Needham analyst Ami Fadia raised the firm’s price target on Biogen (BIIB) to $290 from $256 and keeps a Buy rating on the shares. The company delivered a strong Q3…
Biogen to Present New Data Across Alzheimer's Disease Portfolio at CTAD 2026
Diranersen late-breaking symposium will feature 96-week long-term extension data and additional 76-week biomarker and clinical data from the Phase 2 CELIA study in early Alzheimer's disease Lecanemab ...
Biogen price target raised to $290 from $250 at Baird
Baird raised the firm’s price target on Biogen (BIIB) to $290 from $250 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results where…
Biogen price target raised to $257 from $255 at BofA
BofA raised the firm’s price target on Biogen (BIIB) to $257 from $255 and keeps a Neutral rating on the shares. While Q3 results and FY26 EPS guidance raise at…
Biogen price target raised to $325 from $300 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on Biogen (BIIB) to $325 from $300 and keeps an Overweight rating on the shares following what the firm calls a…
Biogen price target raised to $255 from $215 at Citi
Citi analyst Geoff Meacham raised the firm’s price target on Biogen (BIIB) to $255 from $215 and keeps a Neutral rating on the shares. The firm says Biogen’s Q3 report…
Biogen Earnings Call Transcript: Q3 2026
Q3 revenue rose 11% YoY as growth products and the Apellis acquisition accelerated commercial momentum. 2026 EPS guidance was raised at the low end, while multiple late-stage pipeline readouts are approaching.
Biogen Slides: Q3 2026
Biogen has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 28, 2026.
Biogen Earnings release: Q3 2026
Biogen released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
Biogen price target raised to $230 from $200 at Barclays
Barclays raised the firm’s price target on Biogen (BIIB) to $230 from $200 and keeps an Equal Weight rating on the shares.
Biogen Swings to Loss, Logs Higher Sales
The biotechnology company said the swing to a loss was primarily due to transaction-related charges.
Biogen sees FY26 revenue up by mid-single digit percentage y/y
Full year total revenue is expected to increase by a mid-single digit percentage for 2026 as compared to 2025 driven by continued growth from our Growth Portfolio. Biogen (BIIB) expects…
Biogen reports Q3 adjusted EPS $2.62, consensus $1.99
Reports Q3 revenue $2.8B, consensus $2.63B.
Biogen to Present New Data Across Nephrology Portfolio, Including Long-term EMPAVELI® (pegcetacoplan) Phase 3 Results, at American Society of Nephrology (ASN) Kidney Week
CAMBRIDGE, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new EMPAVELI® (pegcetacoplan) data and additional scientific presentations from its nephrology portfolio, in...